儿童脂质体两性霉素B的治疗药物监测:我们准备好了吗?一项系统综述
该系统综述评估儿童脂质体两性霉素B治疗药物监测的证据,检索PubMed和Embase后纳入6项研究共195名儿童。研究发现儿童中存在显著药代动力学变异,但支持常规治疗药物监测的证据有限,需进一步研究疗效与毒性获益后方可推荐常规监测。
要点
- 儿童脂质体两性霉素B药代动力学变异显著,与年龄、体重、非线性药代动力学及分布容积变化有关。
- 有限证据支持峰浓度/MIC为25-50与最佳疗效相关,AUC24>600 mg·h/L与肾毒性相关。
- 脂质体两性霉素B 2.5-10 mg/kg/日可达峰浓度/MIC>25(MIC为1 mg/L),但支持常规监测的证据有限。
核心结论
- 儿童中观察到显著药代动力学变异,但支持常规脂质体两性霉素B治疗药物监测的证据有限;在推荐常规监测前需进一步研究疗效与毒性获益。
研究设计与样本
- 遵循PRISMA指南系统检索PubMed和Embase数据库,纳入0-18岁儿童脂质体两性霉素B药代动力学/药效学研究,排除综述、少于5例的病例系列、社论和动物研究,共筛选4220项研究后纳入6项,呈现195名儿童数据,使用临床药代动力学批判性评估工具进行质量评价。
主要发现
- 侵袭性念珠菌病和曲霉病是接受脂质体两性霉素B治疗的两类最常见感染。
- 研究显示因年龄(平均年龄范围14天至17岁)、体重、非线性药代动力学和分布容积变化导致显著药代动力学变异。
- 有限证据支持峰浓度/MIC为25-50与最佳疗效相关,AUC24>600 mg·h/L与肾毒性相关。
- 脂质体两性霉素B剂量2.5-10 mg/kg/日据报道在使用MIC 1 mg/L时可达到峰浓度/MIC>25。
关键数值与推荐
- 峰浓度/MIC为25-50与最佳疗效相关(有限证据支持)。
- AUC24>600 mg·h/L与肾毒性相关(有限证据支持)。
- 脂质体两性霉素B 2.5-10 mg/kg/日在使用MIC 1 mg/L时可达到峰浓度/MIC>25。
临床怎么用
- 原文结论未据此给出常规治疗药物监测的推荐,仅指出需进一步研究疗效与毒性获益后方可推荐常规监测。
局限性
- 支持常规脂质体两性霉素B治疗药物监测的证据有限。
- 在推荐常规监测前需进一步研究疗效与毒性获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Therapeutic drug monitoring (TDM) is a tool that supports personalized dosing, but its role for liposomal amphotericin B (L-amb) is unclear. This systematic review assessed the evidence for L-amb TDM in children. OBJECTIVES: To evaluate the concentration-efficacy relationship, concentration-toxicity relationship and pharmacokinetic/pharmacodynamic (PK/PD) variability of L-amb in children. METHODS: We systematically reviewed PubMed and Embase databases following PRISMA guidelines. Eligible studies included L-amb PK/PD studies in children aged 0-18 years. Review articles, case series of <five patients, editorials and animal studies were excluded. Quality assessment was performed using the Critical Appraisal of Clinical Pharmacokinetics tool. The concentration-efficacy and concentration-toxicity relationships and PK/PD variability were analysed. RESULTS: In total, 4220 studies were screened; 6 were included, presenting data on 195 children. Invasive candidiasis and aspergillosis were the two most common infections treated with L-amb. Studies showed significant PK variability due to age (mean age ranged from 14 days to 17 years), body weight, non-linear PK and changes in the volume of distribution. Limited evidence supported a peak concentration/MIC (Cmax/MIC) of 25-50 for optimal efficacy and an AUC24 of >600 mg·h/L for nephrotoxicity. L-amb doses of 2.5-10 mg/kg/day were reported to achieve Cmax/MIC > 25 using an MIC of 1 mg/L. CONCLUSIONS: While significant PK variability was observed in children, evidence to support routine L-amb TDM was limited. Further studies on efficacy and toxicity benefits are required before routine TDM of L-amb can be recommended.
引用
- Lai T, Yeo CY, Rockliff B, et al. Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review. J Antimicrob Chemother. 2024. PMID: 38252921. doi:10.1093/jac/dkae003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。